Background and purpose--------Patients with hyperthyroidism frequently present regional cerebral metabolic changes, but the consequences of endocrine-induced brain changes after thyroid function normalization are unclear. We hypothesized that the changes of regional cerebral glucose metabolism are related to thyroid hormone levels in hyperthyroid patients, and some of these changes can be reversed with antithyroid therapy.
Conclusions--The changes of regional cerebral glucose metabolism are related to thyroid hormone levels in hyperthyroid patients, and some cerebral hypometabolism can be improved after antithyroid therapy. 
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Introduction
Thyroid dysfunctions may be accompanied by numerous neurological and psychiatric changes. The most known is cognitive impairment and depression in hypothyroid patients, as well as an increased risk of cerebrovascular accidents. Also, thyrotoxicosis induces a wide range of cognitive and affective-emotional impairments (1) which is considered one common cause of emotional distress (2) . Nervousness, irritability, impulsiveness, poor concentration, easy fatigability and depressed moods are frequent complaints in thyrotoxicosis, sometimes suggesting primary neuropsychiatric disease (3) . The links between these clinical phenomena and brain metabolic function are poorly understood.
With advances in brain imaging techniques, a combination of endocrine and psychological testing as well as positron emission tomography (PET) may provide there are very few studies on cerebral glucose metabolism dealing with hyperthyroidism-associated changes, which mostly report regional changes of cerebral glucose metabolism before therapy (4) .
Here, we present findings from neuropsychiatric evaluations and cerebral glucose metabolism measurements in individuals with hyperthyroidism before and after antithyroid therapy. Of particular interest were the possible correlation of subjective disability with abnormal function in specific brain regions, and the relationship of these changes following thyroid function recovery.
We hypothesized that the changes of regional cerebral glucose metabolism are related to thyroid hormone levels in hyperthyroid patients, and some of these changes can be reversed with antithyroid therapy.
Methods
Study design
Screening procedures included complete medical examinations, routine laboratory evaluations, Magnetic resonance imaging (MRI, Siemens Trio 3.0 Tesla, Siemens Ltd. China) to exclude potential participants with significant brain diseases, and a neuropsychiatric evaluation. Hyperthyroid patients and healthy control subjects were assessed by measurements of behavioral and somatic complaints and PET scanning twice. For the hyperthyroid group, assessments were performed before F o r P e e r R e v i e w 5 and after antithyroid therapy. An initial dose of methimazole employed was 10mg thrice a day. During treatment, the thyroid hormone levels (free triiodothyronine and free thyroxine) were measured every twenty days. The second PET scans were carried out when the symptoms had disappeared and the thyroid hormone levels were normal.
Then the dose of methimazole was reduced to 10mg a day. Control subjects performed the second scans at the same day of corresponding hyperthyroid patients, but they did not receive methimazole treatment. The index of brain glucose metabolism was normalized, using raw counts from the radiotracer FDG as a surrogate marker. Relative activity, as used in this report, refers to this measure. The protocols were approved by the ethics committees of Huashan Hospital, Fudan University in Shanghai and all studies were performed after informed consent was obtained.
Patients
Ten consecutive patients with Graves'-caused hyperthyroidism ［ mean age 38.7±9.3 yr, 5 females; mean TSH-R antibodies±SD, 24.68±15.09 U/L, normal range:<1U/L］were studied at the Endocrine Department of Huashan Hospital, Fudan University. All patients were newly diagnosed. Before entering the study, all subjects were screened and clinically examined by two senior investigators. The exclusion criteria were endocrine or autoimmune diseases except for hyperthyroidism, hyperthyroidism crisis, pregnancy, no contraception, intake of any psychotropic medication or beta-blocking agents in the 2 months before enrollment, history of bipolar or schizoaffective disorder, and suicide risk (determined on psychiatric Twenty control subjects underwent the same psychiatric screening procedures as hyperthyroid subjects. Inclusion criteria for the age-and gender-matched control group were contraception, no intake of any psychotropic medication, beta-blocking agents, thyroid hormones or antithyroid medication in the past 4 months, and no history of psychiatric, endocrine, neurological or other severe medical disease. In both groups, individuals with current dependence on alcohol and illegal drugs or a positive urine test were excluded.
Data collection
Anthropometric and other information on age, sex, BMI, medication use, diagnosis, and smoking and drinking history were obtained for all patients and control Mental Disorders (DSM) definition (7). Positively and negatively worded items reduce response bias and reversed items act as a lie scale. Total standard scores range from 25 to 100, with higher scores indicative of greater anxiety or depression. Zung stated that total standard scores above or equal to 45 indicated that participants had "clinically significant" anxiety, and above or equal to 50 respondents could be described as having "clinically significant depression" (8, 9). The SAS and SDS have been extensively evaluated, showing good sensitivity, specificity, and reliability for diagnosing anxiety and depression (10) (11) (12) .
PET scan and image reconstruction
Every subject underwent a PET-CT (with 18 F-FDG) scan at the beginning of the study, and all the hyperthyroid patients received a second scan after recovery. Before the PET scan, patients were asked to fast for 8 hours, but had free access to water.
PET scans were performed with a Siemens Biograph 64 PET/CT (Siemens Ltd.
Germany) in three-dimensional (3D) mode. A CT transmission scan was first performed for attenuation correction. The scan was started 45 min after an intravenous bolus injection of 185 MBq of 18 F-FDG a PET and lasted for 10 min. Hanning filters were used during image reconstruction, giving a transaxial and axial cut-off frequency of 0.5. We used normalized count images to measure relative changes in regional glucose metabolism. All studies in patients and normal controls were performed with the subject's eyes open in a dimly lit room with minimal auditory stimulation (13) . 
Data analysis
Clinical data analysis was performed with the use of SPSS software, version 11.5.
For findings before and after therapy, variables were compared by means of a paired Student's t-test for significant change. All P values presented are two-tailed, and values less than 0.05 are considered to be statistically significant.
PET images were pre-processed with statistical parametric mapping (SPM2, half maximum) in the x, y, and z axes, respectively. Mean signal differences over the whole brain were removed by proportional scaling.
Effect of antithyroid therapy on regional glucose metabolism
To characterize pretherapeutic metabolism in hyperthyroid patients with respect to healthy subjects, we performed a group comparison by using a two-sample t-test in SPM2 according to the general linear model at each voxel. The effects of the antithyroid therapy on regional brain metabolism were also estimated using a paired t-test. To evaluate significant differences, we used an approach with the peak threshold set at P=0.001 (uncorrected) for whole brain regions (14, 15 
Correlation between changes in glucose metabolism and clinical outcome in hyperthyroid patients
To quantify regionally-specific metabolic changes, we constructed a 4mm radius volume of interest (VOI) within the image space, centered at the peak voxel of clusters that were significant in SPM analysis. The VOIs were predefined on the basis of brain regions that were significant in both two-sample t-test results of decreased glucose metabolism compared with normal controls and paired t-test results of increased glucose metabolism after antithyroid therapy in patients. We then calculated the relative glucose metabolic rates in Pre-therapy and Post-therapy PET images respectively with ScAnVP software (Version 5.9.1, Center for Neurosciences, the For all analyses, the significance level was set at P<0.05. Statistical analyses were performed using SPSS software, version 11.5.
Results
Clinical results
All Graves'-caused hyperthyroid patients complained about nervousness, irritability, increased heart rate and perspiration, tremors, easy fatigability, heat intolerance, cynorexia and weight loss. One patient experienced a low white blood cell count secondary to methimazole and was recommended to receive Radioisotopes I-131. All others who received the methimazole treatment completed the study.
Thyroid-related hormones of all patients are shown in Table 1 . For Graves' patients, when most of the symptoms had disappeared and all laboratory tests had became normal, the second set of PET scans were performed. The metabolic state became normal within mean seventy-seven days (range:58-102).
The SAS showed that the mean score for anxiety was 48. 35-56.25). Two patients had scores higher than or equal to 50 and both of them had enhanced anxiety, too. The questionnaire showed significantly increased physical complaints, especially heart complaints, dyspnea, perspiration, tremors and fatigue.
After anti-thyroid therapy, all psychometric scores returned to normal levels (P<0.005).
The control subjects performed the second scans at the same day of corresponding hyperthyroid patients, and the average time between PET scans was also seventy-seven days (range:58-102). All control participants had normal levels of TSH, FT3, FT4 and TRAb throughout the study; results of the behavioral assessments did not change significantly in the control group between the two PET scans (data not shown).
Group differences in relative brain activity before treatment
Compared with euthyroid controls, hyperthyroid patients showed no significant increases of regional cerebral glucose metabolism. In contrast, hyperthyroid patients showed a significantly decreased metabolism in the limbic system, temporal lobe, and frontal lobe; mainly in the parahippocampal gyrus (bilateral BA 35 and left BA 28), Table 3 ; Figure 4 ).
Treatment related changes in relative cerebral activity
The second set of PET scans were performed in all patients when the symptoms had disappeared and the thyroid hormone levels (FT3 and FT4) were normal.
Compared with the baseline findings in the hyperthyroid state, the treatment induced a significant cluster of increased metabolic activity in the left parahippocampal gyrus (BA 28/35), right superior frontal gyrus (BA 6), and left fusiform gyrus (BA 37).
However, when compared with euthyroid controls, the glucose metabolism was still significantly decreased in the left parahippocampal gyrus (BA 35) and fusiform gyrus (BA 37) (FDR-corrected P<0.05, Table 4 ; Figure 2 and Figure 3 ). No significant increase was identified for other regions.
The associations between the relative brain activity and thyroid hormone levels as well as emotional complaints of patients
The decrease in both FT3 and FT4 were associated with increased relative glucose metabolic rates in the left parahippocampal gyrus (BA 28) and the right superior frontal gyrus (BA 6) (P<0.05, 
Discussion
This is the first brain functional imaging study about the cerebral metabolic changes in Graves' disease before and after antithyroid treatment. In this study, adult patients with previously untreated hyperthyroidism showed less relative activity in multiple brain regions than healthy control subjects. The differences reached statistical significance in the limbic system (parahippocampus, cingulated and uncus), temporal and frontal cortices, and all brain centers integral to the neurocircuitry of clinical behaviour, mood and memory regulation (18-20). After antithyroid therapy, the patient group displayed a normalization of brain metabolism in some regions, and statistical differences between the two groups were no longer detected. Treatment with methimazole specifically increased regional activity in the left parahippocampus and the right superior frontal gyrus. There also was an association between changes in relative brain activity and disease severity, measured by FT3, FT4, and psychometric scores. The findings suggest that thyroid hormones participate in the modulation of . These studies showed a significantly reduced blood flow of the bilateral temporal-parietal cortex or a decreased metabolism of the uncus and the inferior temporal gyrus. Increased breathing and heart rates might inhibit metabolism of the brainstem. Also, in our study, hyperthyroidism associated regional hypometabolism was noted.
Compared to previous imaging studies of hyperthyroidism, our study detected altered metabolism in regions beyond the uncus, temporal cortex, and prefrontal cortex. In addition to the posterior cingulate and the inferior parietal lobe, new cerebral regions correlated with anxiety and depression scales were identified. These hypothesis is required because researchers must choose specific regions to investigate based on prior evidence. Therefore, critically implicated regions may have been overlooked in most previous studies using ROI approaches. However, a whole brain-based analysis using a voxel level analysis method was performed in our study to localize more areas not previously examined in earlier ROI studies. A key feature of this rapid and automated method of analysis is that it examines differences in grey matter throughout the brain, without the need to pre-specify regions of interest for investigation. This unbiased approach is of value both to confirm the validity of the hypothesis developed in ROI studies and to reveal grey matter differences in areas not previously considered. (Table 4 and Table 5 ). This may implicate primary effects of thyroid hormones that result in the emotional, motivational, cognitive, and behavioral manifestations of affective disorders. Also, the observed correlations to the cerebral metabolism may be directly induced by the elevated thyroid hormone concentrations, and were not a secondary epiphenomenon due to hyperthyroid-associated mood changes. The effect on the cerebrum was mediated by actions of thyroid hormones on thyroid hormone nuclear receptors.
Therefore, with increased disease severity, there is lower metabolism in highly concentration regions of T3 nuclear receptors (18, 29). Thyroid hormones (age-dependent) also modulate the expression of the cerebral glucose transporter protein type 1 (GLUT-1), suggested by reduced 55-kDa GLUT-1 isoform in both hyperthyroid and hypothyroid young rats. The GLUT-1 isoform located at the There were two unexpected findings in our study. One was that the emotional distress-associated regions were not completely consistent with hypoactive regions before treatment. This might be due to the fact that global cerebral metabolism is affected by multiple factors, so a single correlation analysis could not reflect the changes of the whole brain. The other finding was that treatment with methimazole improved memory and constructive abilities when the euthyroid state was established.
Uptake defect in the left parahippocampal gyrus, the fusiform gyrus, and the superior frontal gyrus regions also responded significantly to the medication (FDR-correction at P<0.05). However, other regions were still hypoactive. This might be due to the insufficient period of treatment (mean seventy-seven days). Some brain regions had not returned to normal. More importantly, all of these recovered regions were correlated significantly with the decrease of FT3 or FT4 (Table 4 and Table 5 ). This implicated that the hypoactivity of these regions resulted from thyrotoxicosis, and could increase to normal after antithyroid therapy. Other regions that could not recover might be a secondary epiphenomenon involving other interference factors, such as primary mood disorders. Therefore, the regions mentioned in previous studies (4, 31) on hyperthyroidism may not only reflect the effect of thyroid hormones. In view of the above-mentioned finding, single correlation analysis could not reflect the changes of global brain metabolism. In the future, we may need to explore the Covariation of relative brain activity before treatment in the hyperthyroid group with psychometric scores 180x109mm (600 x 600 DPI)
